104 related articles for article (PubMed ID: 8705215)
1. Determination and reversal of resistance to epirubicin intravesical chemotherapy. A confocal imaging study.
Duffy PM; Hayes MC; Gatrell SK; Cooper A; Smart CJ
Br J Urol; 1996 Jun; 77(6):824-9. PubMed ID: 8705215
[TBL] [Abstract][Full Text] [Related]
2. Determination and reversal of resistance to epirubicin intravesical chemotherapy. A flow cytometric model.
Duffy PM; Hayes MC; Cooper A; Smart CJ
Br J Urol; 1996 Jun; 77(6):819-23. PubMed ID: 8705214
[TBL] [Abstract][Full Text] [Related]
3. Intravesical pH: a potentially important variable affecting efficacy and the further development of anthracycline chemotherapy for superficial bladder cancer.
Harris NM; Duffy PM; Crook TJ; Anderson WR; Sharpe P; Hayes MC; Cooper AJ; Solomon LZ
BJU Int; 2002 Dec; 90(9):957-64. PubMed ID: 12460364
[TBL] [Abstract][Full Text] [Related]
4. Estramustine reversal of resistance to intravesical epirubicin chemotherapy.
Jennings AM; Solomon LZ; Sharpe P; Hayes MC; Cooper AJ; Birch BR
Eur Urol; 1999 Apr; 35(4):327-35. PubMed ID: 10087397
[TBL] [Abstract][Full Text] [Related]
5. Time-lapse live cell imaging and flow analysis of multidrug resistance reversal by verapamil in bladder cancer cell lines.
Featherstone JM; Lwaleed BA; Speers AG; Hayes MC; Birch BR; Cooper AJ
Urology; 2009 Aug; 74(2):378-84. PubMed ID: 19501884
[TBL] [Abstract][Full Text] [Related]
6. The nuclear membrane in multidrug resistance: microinjection of epirubicin into bladder cancer cell lines.
Featherstone JM; Speers AG; Lwaleed BA; Hayes MC; Cooper AJ; Birch BR
BJU Int; 2005 May; 95(7):1091-8. PubMed ID: 15839939
[TBL] [Abstract][Full Text] [Related]
7. Progesterone: a novel adjunct to intravesical chemotherapy.
Lewin J; Cooper A; Birch B
BJU Int; 2002 Nov; 90(7):736-41. PubMed ID: 12410758
[TBL] [Abstract][Full Text] [Related]
8. Localization of anthracycline accumulation in sensitive and resistant urothelial tumor cell lines.
Davies CL; Duffy PM; MacRobert AJ; Loizidou MC; Cooper AJ; Taylor I
Cancer Detect Prev; 1996; 20(6):625-33. PubMed ID: 8939349
[TBL] [Abstract][Full Text] [Related]
9. Multidrug resistance in a urothelial cancer cell line after 3, 1-hour exposures to mitomycin C.
Speers AG; Lwaleed BA; Featherstone JM; Cooper AJ
J Urol; 2007 Nov; 178(5):2171-5. PubMed ID: 17870115
[TBL] [Abstract][Full Text] [Related]
10. Confocal microscopy of idarubicin localisation in sensitive and multidrug-resistant bladder cancer cell lines.
Duffy PM; Hayes MC; Cooper A; Smart CJ
Br J Cancer; 1996 Sep; 74(6):906-9. PubMed ID: 8826856
[TBL] [Abstract][Full Text] [Related]
11. Furosemide reverses multidrug resistance status in bladder cancer cells in vitro.
Speers AG; Lwaleed BA; Featherstone JM; Sallis BJ; Cooper AJ
J Clin Pathol; 2006 Sep; 59(9):912-5. PubMed ID: 16556663
[TBL] [Abstract][Full Text] [Related]
12. Epirubicin and meglumine gamma-linolenic acid: a logical choice of combination therapy for patients with superficial bladder carcinoma.
Harris NM; Anderson WR; Lwaleed BA; Cooper AJ; Birch BR; Solomon LZ
Cancer; 2003 Jan; 97(1):71-8. PubMed ID: 12491507
[TBL] [Abstract][Full Text] [Related]
13. Intravesical epirubicin versus doxorubicin for superficial bladder tumors (stages pTa and pT1): a randomized prospective study.
Ali-el-Dein B; el-Baz M; Aly AN; Shamaa S; Ashamallah A
J Urol; 1997 Jul; 158(1):68-73; discussion 73-4. PubMed ID: 9186325
[TBL] [Abstract][Full Text] [Related]
14. Effect of intravesical instillation on performance of uCYT+ test.
Lodde M; Mian C; Negri G; Vittadello F; Comploj E; Palermo S; Staffler A; Brössner C; Pycha A
Urology; 2004 May; 63(5):878-81. PubMed ID: 15134970
[TBL] [Abstract][Full Text] [Related]
15. Comparing intra-arterial chemotherapy combined with intravesical chemotherapy versus intravesical chemotherapy alone: a randomised prospective pilot study for T1G3 bladder transitional cell carcinoma after bladder-preserving surgery.
Chen J; Yao Z; Qiu S; Chen L; Wang Y; Yang J; Li J
Cardiovasc Intervent Radiol; 2013 Dec; 36(6):1521-1526. PubMed ID: 23511989
[TBL] [Abstract][Full Text] [Related]
16. Delayed high-dose intravesical epirubicin therapy of superficial bladder cancer. A way to reduce the side effects and increase the efficacy--a phase 2 trial.
Bassi P; Spinadin R; Longo F; Saraeb S; Pappagallo GL; Zattoni F; Pagano F
Urol Int; 2002; 68(4):216-9. PubMed ID: 12053020
[TBL] [Abstract][Full Text] [Related]
17. A Hydrogel-Based Epirubicin Delivery System for Intravesical Chemotherapy.
Liu CW; Wu YT; Lin KJ; Yu TJ; Kuo YL; Chang LC
Molecules; 2016 Jun; 21(6):. PubMed ID: 27258243
[TBL] [Abstract][Full Text] [Related]
18. Intravesical instillation of epirubicin: effect on tumour recurrence in patients with dysplastic epithelium after transurethral resection of superficial bladder tumour.
Igawa M; Urakami S; Shirakawa H; Shiina H; Ishibe T; Kadena H; Usui T; Kawanishi M
Br J Urol; 1996 Mar; 77(3):358-62. PubMed ID: 8814838
[TBL] [Abstract][Full Text] [Related]
19. [Effect of prophylactic treatment with intravesical epirubicin in recurrence of superficial bladder tumor].
Pérez Mestre M; Cuñat Albert E; Francisco Mingol V; Arrufat Boix JM; Gallego Gómez J
Arch Esp Urol; 1999 May; 52(4):345-50. PubMed ID: 10380324
[TBL] [Abstract][Full Text] [Related]
20. Intravesical epirubicin treatment following TUR in superficial bladder tumours.
Imamoğlu MA; Bakirtaş H; Yiğitbaşi O; Ersoy H; Sertçelik AN
Arch Esp Urol; 2001 Dec; 54(10):1147-53. PubMed ID: 11852530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
